Floatz logo

Ribociclib

Ribociclib

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Ribociclib cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
cc-5013
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
Ckd-581
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
Letrozole
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
D
Zoladex
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
D

View all 9 →

Same molecule, other indications

Ribociclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
HR+/HER2- Breast CancerDormant
BB
Indicative ·
70 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →